(Total Views: 217)
Posted On: 06/03/2017 8:03:50 AM
Post# of 22851
As shown on the ASCO Program for June 2, 2017. I tried to correlate when the stock really took a dive to determine if something at the presentation made the stock drop. As shown below, the CYTR presentation ended at 3:12 PM. The stock closed the day, 4:00 PM, at $.82 so the downward presssure occurred in the After-Hour market.
My problem is that my NASDAQ After-Hour screen only goes back two pages of transactions for which the earliest transaction I see is at 18:50:25 and the price was down to $.685 (already down from what we know to $.60 -the low) and from that point began to move up to $.72 before settling the night at $.70.
From what I can discern based on the above, it was a matter of profit-taking which caused the stock to decline so rapidly in AH.
ASCO PROGRAM FOR CYTR 6/02/2017
Abstract 11000
Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas.
3:00 PM - 3:12 PM
Sant P. Chawla, MD - First Author
Director, Sarcoma Oncology Center
My problem is that my NASDAQ After-Hour screen only goes back two pages of transactions for which the earliest transaction I see is at 18:50:25 and the price was down to $.685 (already down from what we know to $.60 -the low) and from that point began to move up to $.72 before settling the night at $.70.
From what I can discern based on the above, it was a matter of profit-taking which caused the stock to decline so rapidly in AH.
ASCO PROGRAM FOR CYTR 6/02/2017
Abstract 11000
Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas.
3:00 PM - 3:12 PM
Sant P. Chawla, MD - First Author
Director, Sarcoma Oncology Center
(0)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
Scroll down for more posts ▼
